Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Overweight
Interventions:   Drug: Liraglutide;   Other: Observation alone
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting - verified February 2016

An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DS-8500a;   Drug: placebo
Sponsor:   Daiichi Sankyo Co., Ltd.
Not yet recruiting - verified January 2016

The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

Condition:   Type 2 Diabetes
Interventions:   Drug: GIP Bolus;   Drug: GIP Clamp;   Procedure: Oral glucose tolerance test (OGTT);   Procedure: hyperglycemic clamp
Sponsor:   Diabeteszentrum Bad Lauterberg im Harz
Completed - verified February 2016

The Curative Effect of the Length of the Jejunum Exclusion in Grstric Bypass Surgery for Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Procedure: short biliarypancreatic limb;   Procedure: long biliarypancreatic limb
Sponsor:   Weidong Tong
Recruiting - verified January 2016

Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy

Condition:   Type 2 Diabetes
Interventions:   Other: 1: incretin-based therapy;   Other: 2: other antidiabetic
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Assistance Publique Hopitaux De Marseille;   Institut National de la Santé Et de la Recherche Médicale, France;   France: Centre National de la Recherche Scientifique;   Collège de France;   University of Paris 5 - Rene Descartes;   Pierre and Marie Curie University;   University Paris 7 - Denis Diderot;   Aix Marseille Université
Not yet recruiting - verified January 2016

Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects

Condition:   Diabetes
Interventions:   Device: Continuous Glucose Monitoring System (CGMS);   Behavioral: Food log
Sponsors:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified February 2016

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: LGD-6972 Solution;   Drug: LGD-6972 Capsules
Sponsors:   Ligand Pharmaceuticals;   Medpace, Inc.
Not yet recruiting - verified January 2016

The Effects of Culturally Specific Cooking Classes on Diabetes Control in Chinese Canadian Persons

Condition:   Diabetes Mellitus Type 2
Intervention:   Dietary Supplement: Culturally specific chinese-canadian dietary cooking classes for persons with diabetes
Sponsor:   Vancouver General Hospital
Not yet recruiting - verified January 2016

Hypoglycaemia in People With Type 2 Diabetes in Primary Care

Conditions:   Diabetes Mellitus, Type 2;   Hypoglycemia
Intervention:  
Sponsors:   University of Leicester;   Primary Care Diabetes Society, UK
Enrolling by invitation - verified January 2016

Vaccine Efficacy in Diabetic and Elderly Patients

Condition:   Inflammation
Intervention:   Biological: Influenza Virus Vaccine
Sponsors:   Tulane University School of Medicine;   Louisiana Clinical and Translational Science Center
Recruiting - verified February 2016

The Relationship Between Advanced Glycation Endproducts and Diabetes

Conditions:   Diabetic Retinopathy;   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   University of Colorado, Denver
Not yet recruiting - verified January 2016

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

Condition:   Type 2 Diabetes Mellitus (T2DM)
Intervention:   Behavioral: Lifestyle intervention
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified January 2016

Effects of Ginger Supplementation on NF-KB in Peripheral Blood Mononuclear Cells in Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Ginger;   Dietary Supplement: placebo
Sponsor:   Tehran University of Medical Sciences
Completed - verified January 2016

12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin 100 mg;   Drug: DS-8500a 25mg;   Drug: placebo
Sponsor:   Daiichi Sankyo Inc.
Recruiting - verified January 2016

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide Liquid Auto-injector;   Drug: Albiglutide Lyophilized DCC Pen Injector;   Drug: Placebo Liquid Auto-injector;   Drug: Placebo Lyophilized DCC Pen injector
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified February 2016

Loop Duodenal Switch Surgery in Morbidly Obese Patients

Conditions:   Obesity;   Type-2 Diabetes Mellitus
Intervention:   Procedure: Loop duodenal switch
Sponsor:   Medical College of Wisconsin
Recruiting - verified January 2016

CGV in Newly Diagnosed Type 2 Diabetes Patients: Effect of Dietary Interventions in the Human Microbiome

Condition:   Diabetes Mellitus Type 2 in Obese
Intervention:   Behavioral: Social Cognitive Theory Tailored Behavioral Intervention
Sponsors:   New York University School of Medicine;   National Institutes of Health (NIH)
Not yet recruiting - verified January 2016

Salivary Transcriptome Biomarkers for Early Diabetes Detection

Conditions:   Pre-diabetes;   Type II Diabetes;   Insulin Resistance
Intervention:  
Sponsor:   PeriRx
Recruiting - verified December 2015

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: ITCA 650 60 mcg/day
Sponsor:   Intarcia Therapeutics
Recruiting - verified February 2016

Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: LY2409021;   Drug: LY2409021 placebo;   Procedure: OGTT;   Procedure: IIGI;   Procedure: Standardised liquid meal
Sponsors:   University Hospital, Gentofte, Copenhagen;   Eli Lilly and Company
Enrolling by invitation - verified December 2015

Metabolic Effects of Angiotensin-(1-7)

Conditions:   Obesity;   Insulin Resistance;   Hypertension;   Metabolic Cardiovascular Syndrome
Interventions:   Drug: Angiotensin-(1-7);   Drug: Saline
Sponsor:   Vanderbilt University
Recruiting - verified February 2016

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo matching ertugliflozin;   Drug: Metformin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Not yet recruiting - verified February 2016

INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Intervention 1;   Other: Intervention 2
Sponsors:   Jordi Gol i Gurina Foundation;   Sanofi
Recruiting - verified January 2016

Metformin Plus Sorafenib for Advanced HCC

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Sorafenib;   Drug: Metformin
Sponsors:   Tianjin Medical University Cancer Institute and Hospital;   First Affiliated Hospital of Harbin Medical University;   Harbin Medical University;   Liaoning Tumor Hospital & Institute;   Shanghai Zhongshan Hospital;   Fudan University
Recruiting - verified December 2015

FGF-21 and Exercise in Relation to Insulin Secretion

Condition:   Physical Activity
Intervention:   Other: spiroergometry
Sponsor:   Charite University, Berlin, Germany
Recruiting - verified January 2016

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified January 2016

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Placebo;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: U-500R
Sponsor:   Eli Lilly and Company
Recruiting - verified January 2016

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2016

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine (U300);   Device: MyStar DoseCoach
Sponsor:   Sanofi
Recruiting - verified February 2016

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Ipragliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2016

Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes

Conditions:   Diabetes;   Periodontitis
Interventions:   Device: Hyperbaric Oxygen therapy;   Other: Conventional Wound Therapies
Sponsor:   Loma Linda University
Recruiting - verified January 2016

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified January 2016

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

Condition:   Hyperglycemia
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Regular Human Insulin;   Drug: Insulin glargine;   Drug: Supplemental insulin (Insulin lispro);   Drug: Supplemental insulin (Insulin aspart)
Sponsor:   Emory University
Recruiting - verified January 2016

A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glargine insulin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified October 2015

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE
Sponsor:   Sanofi
Recruiting - verified February 2016

A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
Sponsor:   Takeda
Recruiting - verified January 2016

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Type 2
Interventions:   Drug: ORMD-0801;   Drug: Placebo Comparator
Sponsors:   Oramed, Ltd.;   Integrium
Active, not recruiting - verified February 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Conditions:   Type 2 Diabetes Mellitus,;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Glimepiride;   Drug: Placebo for dapagliflozin;   Drug: Placebo for saxagliptin;   Drug: Placebo for glimepiride
Sponsor:   AstraZeneca
Recruiting - verified January 2016

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified January 2016

Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PEX168(100µg);   Drug: PEX168(200µg);   Drug: Placebo;   Drug: Metformin
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Recruiting - verified January 2016

Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PEX168(100µg);   Drug: PEX168(200µg);   Drug: Placebo
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Active, not recruiting - verified January 2016

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

The Diabetes Medication Adherence Promotion Intervention Trial

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Diabetes MAP Intervention
Sponsors:   Vanderbilt University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2016

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

Condition:   Healthy
Interventions:   Drug: PEX168;   Drug: Warfarin
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Not yet recruiting - verified January 2016

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

Condition:   Healthy
Interventions:   Drug: PEX168;   Drug: Digoxin
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Recruiting - verified January 2016

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified February 2016

A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease

Condition:   Type II Diabetes Mellitus
Intervention:   Dietary Supplement: Musashino T2DM diet
Sponsor:   Celio Technology Inc.
Completed - verified May 2015

A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Device: Harmony 1 Sensor
Sponsor:   Medtronic Diabetes
Not yet recruiting - verified January 2016

Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear

Conditions:   Diabetes Mellitus Type 2;   Sensory Neuropathy;   Foot Ulcer, Diabetic
Intervention:   Device: Kyboot shoes
Sponsors:   Sheba Medical Center;   Kybun AG
Completed - verified January 2016

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus.

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   AstraZeneca;   Antaros Medical AB;   Bioventure Hub;   43183 Mölndal;   Sweden
Recruiting - verified February 2016

FreeStyle Libre Pro Use in Primary & Secondary Care

Condition:   Diabetes Mellitus
Interventions:   Device: FreeStyle Libre Pro 4 sensor wears, 2 with reviews;   Device: FreeStyle Libre Pro 6 sensor wears, 4 with reviews;   Device: FreeStyle Libre Pro 3 sensor wears
Sponsor:   Abbott Diabetes Care
Active, not recruiting - verified February 2016

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified January 2016

Glucose Metabolism, Muscle Mass/Function and Inflammation in the Elderly

Conditions:   Sarcopenia;   Diabetes Mellitus
Intervention:  
Sponsors:   Catholic University of the Sacred Heart;   University of Rome Tor Vergata;   Fondazione Roma
Not yet recruiting - verified January 2016

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified February 2016

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2016

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PEX168;   Drug: Simvastatin
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Active, not recruiting - verified May 2015

Effects of CPAP and Massive Weight Loss on Inflammation Induced by Obstructive Sleep Apnea

Conditions:   Obesity;   Obstructive Sleep Apnea
Intervention:   Device: Continuous Positive Airway Pressure (CPAP)
Sponsor:   University of Aarhus
Recruiting - verified January 2016

Variable Interval Versus Set Interval Aflibercept for DME

Conditions:   Cystoid Macular Edema;   Diabetic Macular Edema
Intervention:   Drug: Intravitreal Aflibercept Injection
Sponsors:   California Retina Consultants;   Regeneron Pharmaceuticals
Recruiting - verified January 2016

Financial Incentives and Text Messaging to Improve African American Womens' Glycemic Control

Condition:   Diabetes Mellitus
Intervention:   Behavioral: IM/SMS + Incentive Condition
Sponsor:   University of California, Los Angeles
Recruiting - verified January 2016

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Condition:   Physical Activity
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   Christopher Bell;   AstraZeneca
Recruiting - verified January 2016

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Teneligliptin;   Drug: Canagliflozin;   Drug: Placebo
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified January 2016

Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2016

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472;   Drug: Placebo
Sponsor:   Takeda
Active, not recruiting - verified January 2016

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified February 2016

The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   University of Padova;   Azienda Ospedaliera di Padova
Recruiting - verified January 2016

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   Prof. Dr. Thomas Forst
Recruiting - verified January 2016

An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: gemigliptin
Sponsor:   LG Life Sciences
Active, not recruiting - verified January 2016

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Active, not recruiting - verified September 2015

A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

Conditions:   Type 2 Diabetes;   Non-alcoholic Fatty Liver Disease
Intervention:   Drug: Oral administration of Lobeglitazone
Sponsor:   Yonsei University
Completed - verified January 2016

A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria

Condition:   Type 2 Diabetes Mellitus and Microalbuminuria
Interventions:   Drug: TAK-272 tablets;   Drug: Placebo tablets;   Drug: Candesartan cilexetil tablets
Sponsor:   Takeda
Recruiting - verified January 2016

Insulin Sensitivity, Irisin and Adipokines as Outcome Parameters in Patients Undergoing Cardiac Surgery

Conditions:   Insulin Resistance;   Diabetes Mellitus Type 2;   Other Functional Disturbances Following Cardiac Surgery
Intervention:   Procedure: Cardiac surgery
Sponsors:   University Hospital, Basel, Switzerland;   McGill University
Recruiting - verified January 2016

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Condition:   Insulin Sensitivity
Interventions:   Drug: Eritoran;   Other: D5W
Sponsor:   Nicolas Musi, MD
Recruiting - verified January 2016

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Alogliptin
Sponsor:   Takeda
Recruiting - verified January 2016

A Study of Once-Daily RO6811135 in Participants With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Metformin;   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Redox Imbalance and the Development of Cystic Fibrosis Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Cystic Fibrosis
Interventions:   Drug: Oral Glucose Tolerance Test;   Other: High Glycemic Index Meal;   Other: Low Glycemic Index Meal
Sponsors:   Emory University;   Cystic Fibrosis Foundation Therapeutics
Recruiting - verified January 2016

Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus

Conditions:   Depression;   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Physician Supported Care;   Other: Usual care
Sponsors:   Adwin Life Care;   NMP Medical Research Institute
Completed - verified January 2016

Hypertriglyceridaemia - Cause and Effects

Condition:   Hypertriglyceridaemia
Intervention:  
Sponsor:   Central Manchester University Hospitals NHS Foundation Trust
Recruiting - verified January 2016

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Sitagliptin
Sponsor:   Chipscreen Biosciences, Ltd.
Recruiting - verified January 2016

Paraoxonase and HDL Qualities in Glycaemia and Inflammation

Conditions:   Diabetes.;   Bariatric Surgery.
Intervention:  
Sponsors:   Central Manchester University Hospitals NHS Foundation Trust;   British Heart Foundation;   Juvenile Diabetes Research Foundation
Recruiting - verified January 2016

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified February 2016

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Placebo
Sponsor:   Chipscreen Biosciences, Ltd.
Recruiting - verified January 2016

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin medium dose;   Drug: empagliflozin high dose;   Drug: empagliflozin low dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5mg;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified January 2016

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Biological: BMS-986036;   Biological: Placebo (Matching with BMS-986036)
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified January 2016

Nutritional Intervention of Type II Diabetes Mellitus by Vitamin D in Qatar

Condition:   Insulin Resistance
Intervention:   Dietary Supplement: Vitamin D
Sponsor:   Supreme Council Of Health, Qatar
Recruiting - verified February 2016

Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes

Conditions:   Type 1 Diabetes Mellitus;   Exercise;   Hypoglycemia;   Carbohydrate Metabolism
Interventions:   Procedure: IHE first, CONT second;   Procedure: CONT first, IHE second;   Procedure: GLU first, GLU-FRU second;   Procedure: GLU-FRU first, GLU second
Sponsors:   University Hospital Inselspital, Berne;   University of Bern;   University of Lausanne
Enrolling by invitation - verified February 2016

Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound

Conditions:   Hepatitis C;   Hepatitis B;   Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Intervention:   Device: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR);   Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified January 2016

Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Chang Gung Memorial Hospital
Completed - verified January 2016

Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: glimepiride;   Drug: glargine and metformin
Sponsor:   Qifu Li
Completed - verified January 2016

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified January 2016

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Glimerpiride;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Glimepiride;   Drug: Metformin;   Drug: Sitagliptin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified February 2016

Linagliptin Inpatient Trial

Condition:   Type 2 Diabetes
Interventions:   Drug: Linagliptin;   Drug: Basal Bolus;   Drug: Linagliptin;   Drug: Linagliptin + 50% Glargine dose on discharge;   Drug: Linagliptin + 80% Glargine
Sponsors:   Emory University;   Boston Medical Center;   Rush University;   University of Denver
Recruiting - verified February 2016

Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Conditions:   Stage IA Pancreatic Adenocarcinoma;   Stage IB Pancreatic Adenocarcinoma;   Stage IIA Pancreatic Adenocarcinoma;   Stage IIB Pancreatic Adenocarcinoma
Interventions:   Drug: Gemcitabine;   Drug: Metformin;   Drug: placebo
Sponsor:   Xian-Jun Yu
Recruiting - verified February 2016

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Conditions:   Breast Cancer;   Breast Tumors;   Cancer of Breast
Interventions:   Drug: Metformin;   Drug: Atorvastatin;   Procedure: Breast surgery
Sponsor:   Columbia University
Recruiting - verified February 2016

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 2015

Left Ventricular DYsfunction in DiAbetes

Conditions:   Diabetes Mellitus, Type 2;   Heart Diseases;   Left Ventricular Dysfunction
Intervention:  
Sponsor:   Heart Care Foundation
Completed - verified October 2013

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified January 2016

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2016

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004
Sponsor:   Boehringer Ingelheim
Completed - verified January 2016

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Diabetes Lifestyle Assessment and Educational Tools

Condition:   Type 2 Diabetes Mellitus
Interventions:   Procedure: I-ACE intervention;   Procedure: Standard Lifestyle Advice
Sponsors:   Ofra Kalter-Leibovici MD;   The Gertner Institute for Epidemiology & Health Policy Research;   Clalit Health Services;   European Foundation for the Study of Diabetes
Active, not recruiting - verified February 2016

Genetics of Insulin and Incretins in Cystic Fibrosis

Condition:   Cystic Fibrosis
Interventions:   Genetic: Blood or Saliva Sample Collection;   Other: Glucose -potentiated arginine (GPA) stimulation tests
Sponsors:   Children's Hospital of Philadelphia;   University of Pennsylvania
Recruiting - verified February 2016

Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study

Conditions:   Healthy;   Gestational Diabetes Mellitus;   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   University of California, Davis;   California Dairy Research Foundation
Active, not recruiting - verified February 2016

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk

Condition:   Type 2 Diabetes
Interventions:   Other: HbA1c measurement;   Other: Oral Glucoce Tolerance Test
Sponsor:   Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète
Recruiting - verified August 2015

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified January 2016

Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease

Conditions:   Fatty Liver;   Dyslipidemias;   Diabetes Mellitus
Interventions:   Drug: atorvastatin;   Drug: Vitamin E
Sponsors:   Xin Gao;   Pfizer
Recruiting - verified February 2016

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2016

Dental Implant Study Comparing Two Types of Metals Used for Dental Implants

Condition:   Tooth Replacement
Interventions:   Device: Zimmer Trabecular Metal Test Cylinder;   Device: Zimmer Titanium Test Cylinder
Sponsors:   University of North Carolina, Chapel Hill;   Zimmer Dental
Completed - verified January 2016

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Glipizide;   Drug: Placebo to glipizide;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified January 2016

Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers

Conditions:   Obesity;   Type 2 Diabetes;   Gestational Diabetes
Intervention:  
Sponsors:   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Thrasher Research Fund
Recruiting - verified February 2016

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers

Conditions:   Type I Diabetes Mellitus With Ulcer;   Type II Diabetes Mellitus With Ulcer
Intervention:   Biological: ABMD-MSC
Sponsor:   Sheba Medical Center
Not yet recruiting - verified January 2016

Enhancing Informal Caregiving to Support Diabetes Self-Management

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Telemonitoring + self-management support
Sponsors:   University of Michigan;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2016

Diabetes Outcomes and Nurse Case Manager Study

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Nurse Case Management;   Behavioral: standard diabetologist care
Sponsors:   BCDiabetes.Ca;   Sanofi
Completed - verified January 2016

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified January 2016

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Peer Mentoring
Sponsor:   VA Office of Research and Development
Recruiting - verified January 2016

The VALDIATE-D Study

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Drug: Calcitriol and Lisinopril;   Drug: Placebo
Sponsor:   Brigham and Women's Hospital
Completed - verified February 2016

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-5823;   Other: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Gliclazide;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Liraglutide in Type 1 Diabetes

Conditions:   Diabetes Mellitus, Type 1;   Overweight
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsors:   Steno Diabetes Center;   University Hospital, Gentofte, Copenhagen;   University of Copenhagen
Completed - verified January 2016

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2016

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952;   Drug: RO6807952;   Drug: liraglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified February 2016

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Glycemic Rescue 1;   Drug: Glycemic Rescue 2;   Biological: Glycemic Rescue 3
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified August 2015

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

Conditions:   Depression;   Impaired Glucose Tolerance
Interventions:   Other: The Blues Program;   Other: Hey Durham
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health Clinical Center (CC)
Completed - verified January 2016

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: lisinopril;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Conditions:   Coronary Artery Disease;   Decreased Left Ventricular Function
Intervention:   Drug: Exenatide
Sponsors:   Charles University, Czech Republic;   Eli Lilly and Company
Completed - verified January 2016

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Sulfonylurea;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Diabetic Treatment Adherence

Condition:   Endocrine System Diseases
Interventions:   Drug: Metformin;   Behavioral: Questionnaires
Sponsors:   M.D. Anderson Cancer Center;   Agency for Healthcare Research and Quality (AHRQ)
Active, not recruiting - verified January 2016

Home Exercise for Older Diabetics

Condition:   Diabetes Mellitus Type 2
Interventions:   Behavioral: home exercise/physical activity (PA) enhancement program with behavioral support;   Behavioral: flex and toning health education program
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2016

Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.

Condition:   Diabetes
Interventions:   Drug: Group 1: Metformin;   Dietary Supplement: Group 2: Cinnamon Bark;   Dietary Supplement: Group 3: Cinnulin PF
Sponsor:   Mike O'Callaghan Federal Hospital
Recruiting - verified February 2016

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified January 2016

Characterization of Metabolic Biomarkers in Varying Subjects

Conditions:   Obesity;   Type 2 Diabetes
Intervention:  
Sponsor:   CPL Associates
Recruiting - verified January 2016

Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Completed - verified January 2016

Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes

Conditions:   Overweight;   Obesity;   Type 2 Diabetes
Interventions:   Behavioral: Caloric restriction;   Behavioral: Diet intervention and structured exercise training program
Sponsor:   Institut de Recherches Cliniques de Montreal
Active, not recruiting - verified January 2016

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-0941;   Drug: Comparator: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2016

A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours

Condition:   Diabetes
Intervention:   Device: Subcutaneous glucose monitoring device
Sponsors:   BioTex, Inc.;   Endocrinoloogy Associates Houston
Completed - verified February 2016

Januvia Re-examination Study (MK-0431-181)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Sulfonylurea;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified February 2016

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: pioglitazone
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: RO5095932;   Drug: RO5095932
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-1006 DFC;   Drug: MK-1006 FCT
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: RO5095932;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

Conditions:   Obesity, Morbid;   Diabetes Mellitus, Type 2;   Gastric Bypass
Intervention:  
Sponsors:   CPL Associates;   Synergy Bariatrics;   Sisters of Charity Hospital;   The New York State Center of Excellence in Bioinformatics & Life Sciences
Completed - verified January 2016

Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes

Condition:   Diabetes Mellitus
Intervention:   Procedure: Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Sponsors:   Florida Atlantic University;   Advanced Diabetes Treatment Centers
Terminated - verified February 2016

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK8245 5 mg (twice a day) b.i.d.;   Drug: MK8245 50 mg b.i.d.;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes

Conditions:   Type 2 Diabetes;   Oxidative Stress
Intervention:   Biological: ascorbic acid (Vitamin C)
Sponsor:   In-Young Choi, Ph.D.
Active, not recruiting - verified January 2016

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Condition:   Diabetes Mellitus Non-insulin-dependent
Intervention:   Drug: sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO5027838;   Drug: RO5027838;   Drug: RO5093151;   Drug: RO5093151
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

Conditions:   Diabetes Mellitus Type 1;   Diabetes Mellitus Type 2
Intervention:   Drug: Sitagliptin (Januvia)
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified January 2016

A Study of Taspoglutide in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-1006;   Drug: Comparator: Placebo comparator
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK1006;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: pioglitazone;   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified January 2016

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RG1511
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4876904
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: rosiglitazone;   Drug: metformin or sulfonylurea
Sponsors:   Dr. Milan Gupta;   GlaxoSmithKline
Completed - verified January 2016

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Effect of EGCG on the Body's Response to Insulin

Conditions:   Hypertension;   Obesity;   Type 2 Diabetes;   Insulin Resistance
Intervention:   Drug: EGCG
Sponsor:   University of Maryland
Withdrawn - verified January 2016

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: voglibose
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Glyburide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Simvastatin
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: sitagliptin phosphate (MK0431);   Drug: Comparator: pioglitazone;   Drug: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks;   Drug: Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sitagliptin;   Drug: Comparator: Placebo;   Drug: rosiglitazone;   Drug: metformin;   Drug: glipizide
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day;   Drug: comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Metformin;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily);   Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily);   Drug: Comparator: Placebo (Phase A)/Metformin (Phase B);   Drug: Comparator: Metformin 500 mg b.i.d.;   Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.;   Drug: Comparator: Metformin 1000 mg b.i.d.
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Comparator: Sitagliptin;   Drug: Comparator: Placebo;   Drug: Comparator: Pioglitazone;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016